{"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}],"groups":[{"description":"Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.","id":"BG000","title":"Experimental: Nab-Sirolimus"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"27","upperLimit":"78","value":"60"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}],"title":"0 (Fully active, able to carry on all pre-disease performance without restriction)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}],"title":"1 (Restricted in physically strenuous activity but ambulatory and able to carry out light work)"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Score","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"description":"For the assessment of overall tumor burden and measurable advanced disease (metastatic or locally advanced) at baseline, computed tomography (CT) or contrast enhanced magnetic resonance imaging (MRI) could be used, as long as the same modality was used throughout the study. Baseline scans were done at done within 4 weeks of starting therapy and must have included (as clinically indicated), chest, abdominal, and pelvic CT or MRI.","paramType":"COUNT_OF_PARTICIPANTS","title":"Metastatic PEComa","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"description":"For the assessment of overall tumor burden and measurable advanced disease (metastatic or locally advanced) at baseline, computed tomography (CT) or contrast enhanced magnetic resonance imaging (MRI) could be used, as long as the same modality was used throughout the study. Baseline scans were done at done within 4 weeks of starting therapy and must have included (as clinically indicated), chest, abdominal, and pelvic CT or MRI.","paramType":"COUNT_OF_PARTICIPANTS","title":"Locally Advanced, Inoperable PEComa","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Systemic Therapy for Advanced PEComa","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Uterus"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Pelvis, extrauterine"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Retroperitoneum"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Lung"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Kidney"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Aorta"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Brain"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Liver"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Muscle"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Ovary"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Small Bowel"}],"denoms":[{"counts":[{"groupId":"BG000","value":"34"}],"units":"Participants"}]}],"description":"PEComa can be located at various anatomic sites.","paramType":"COUNT_OF_PARTICIPANTS","title":"Primary Tumor Location of PEComa","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"1 metastatic site (best)"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"2 metastatic sites"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"3 metastatic sites"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":">3 metastatic sites (worst)"}],"denoms":[{"counts":[{"groupId":"BG000","value":"29"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients with metastatic lesions n = 29.","title":"Number of Metastatic Sites","unitOfMeasure":"Participants"}],"populationDescription":"Safety Analysis Set: patients treated with nab-sirolimus (N = 34)"}